Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | BLM | P54132 | 3/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | MPO | P05164 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29751089 | 1.00 | TNF (0.61) | TNFGPR84KMT2ALMNAKDM4E | |
| SCHEMBL6844425 | 1.00 | TNF (0.61) | TNFGPR84KMT2ALMNAKDM4E | |
| Hydrochloric Acid SCHEMBL29750798 | 0.99 | TNF (0.60) | TNFGPR84KMT2ALMNAKDM4E | |
| SCHEMBL4641967 | 0.89 | TNF (0.51) | TNFGPR84KMT2ALMNAKDM4E | |
| SCHEMBL31414601 | 0.88 | KMT2A (0.60) | TNFGPR84KMT2ALMNAKDM4E | |
| SCHEMBL19911037 | 0.86 | TNF (0.58) | TNFGPR84KMT2ALMNAKDM4E | |
| SCHEMBL21315702 | 0.86 | TNF (0.58) | TNFGPR84KMT2ALMNAKDM4E | |
| SCHEMBL29750800 | 0.83 | TNF (0.61) | TNFGPR84KMT2ALMNAKDM4E | |
| SCHEMBL4736751 | 0.83 | SCN9A (0.50) | TNFGPR84KMT2ALMNAKDM4E | |
| Hydrochloric Acid SCHEMBL29750797 | 0.82 | TNF (0.60) | TNFGPR84KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | UNIV DANMARKS TEKNISKE (DK) | 2025-11-20 | — | — | US | disclosed |
| US-20120142750-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2012-06-07 | — | — | US | disclosed |
| US-20120142750-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2012-06-07 | — | — | US | disclosed |
| US-20090155311-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | MED. COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155311-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | MED. COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1956016-A1 | Bicyclic acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
| US-20040259256-A1 | Methods of unnatural amino acid incorporation in mammalian cells | NEURION PHARMACEUTICALS | 2004-12-23 | — | — | US | disclosed |
| WO-2004085463-A2 | METHODS OF UNNATURAL AMINO ACID INCORPORATION IN PROTEINS IN MAMMALIAN CELLS | NEURION PHARMACEUTICALS (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155311-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | IDO2, IDO1, INMT | TNF 2865/4885GPR84 603/4885KMT2A 461/4885 |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | TNF 1517/4885GPR84 304/4885KMT2A 1405/4885 |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | INMT, KARS1, MIA3 | TNF 4064/4885GPR84 3005/4885KMT2A 445/4885 |
| US-20120142750-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | IDO2, IDO1, INMT | TNF 2865/4885GPR84 603/4885KMT2A 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.